Clinical significance of SQSTM1/P62 and nuclear factor-κB expression in pancreatic carcinoma

• Published in: World journal of gastrointestinal oncology 2020-07, Vol.12 (7), p.719-731
• Main Authors: Zhang, Zhao-Yang, Guo, Sen, Zhao, Rui, Ji, Zhi-Peng, Zhuang, Zhuo-Nan
• Format: Article
• Language: English
• Subjects: Basic Study
• ISSN: 1948-5204; 1948-5204
• DOI: 10.4251/wjgo.v12.i7.719

BACKGROUNDOverexpression of SQSTM1 (sequestosome 1, P62) and nuclear factor-κB (NF-κB) plays an important role in the invasion and metastasis of a variety of malignant tumors. AIMTo explore the expression of P62 and NF-κB in pancreatic cancer and their relationship with clinicopathological features. METHODSThe expression levels of P62 and NF-κB were analyzed by immunohistochemistry with a tissue chip containing 40 cases of human pancreatic carcinoma. Then we analyzed the correlation among P62 expression, phospho-P65 expression, and clinicopathological features of pancreatic carcinoma samples. RESULTSP62 expression was mainly observed in the cytoplasm of pancreatic carcinoma cells. Phosphorylated P65 (phospho-P65) was mainly expressed in the nucleus and cytoplasm of pancreatic carcinoma cells. There was a significant difference in P62 expression among T stages. And a significant difference in phosphor-P65 expression among pathology types was noted. In the cases with strongly positive P62 expression, significant differences were found in age. And there were significant differences in T stage and tumor-node-metastasis stage in the cases with strongly positive phosphor-P65 expression. CONCLUSIONIn pancreatic carcinoma, P62 expression is significantly correlated with T stage. It may be a valuable malignant indicator for human pancreatic carcinoma.